ArriVent BioPharma doses first patient in Phase 1 trial of dual‑target ADC ARR‑002 for ovarian and endometrial cancer
ArriVent BioPharma announced that the first patient was dosed in the U.S. Phase 1 study (NCT07755436) of ARR‑002, a tetravalent antibody‑drug conjugate that targets both MUC16 and NaPi2b in advanced ovarian or endometrial cancer. The drug uses site‑specific conjugation to vcMMAE with a drug‑to‑antibody ratio of 4. In August 2026 the company signed an exclusive license with Shanghai Allist Pharmaceuticals to develop and commercialize ARR‑002 in Greater China, while retaining rights elsewhere.
Why it matters
The first‑patient dosing marks a key clinical‑development milestone that moves ARR‑002 into human testing, potentially increasing investor interest and valuation. The Greater China licensing agreement expands the drug’s commercial opportunity in a large market.
Key facts
- 1The first patient was dosed on Oct 12 2026 in the U.S. Phase 1 trial (NCT07755436). stocktitan.net
- 2ARR‑002 targets the MUC16 and NaPi2b proteins. stocktitan.net
- 3The ADC uses site‑specific conjugation to vcMMAE at a drug‑to‑antibody ratio of 4. stocktitan.net
- 4ArriVent entered an exclusive licensing agreement with Shanghai Allist Pharmaceuticals in August 2026 for development and commercialization of ARR‑002 in Greater China. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.